Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
about
Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNSFluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castleThe circumventricular organs participate in the immunopathogenesis of experimental autoimmune encephalomyelitis.New and emerging disease modifying therapies for multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisNatalizumab for relapsing remitting multiple sclerosisNatalizumab for relapsing remitting multiple sclerosisFilamin binds to the cytoplasmic domain of the beta1-integrin. Identification of amino acids responsible for this interactionExpression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patientsCXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunityTheiler's virus infection: a model for multiple sclerosisGLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyThe interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brainImpact of Exercise on Innate Immunity in Multiple Sclerosis Progression and SymptomatologySelective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabExploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisIntegrin-based therapeutics: biological basis, clinical use and new drugsMonoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomesOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionLeukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory diseaseThe immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS)Multiple sclerosis-a quiet revolutionInflammatory monocytes and the pathogenesis of viral encephalitisReview article: anti-adhesion therapies for inflammatory bowel diseaseAn update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerationsVedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Analysis of behavior and trafficking of dendritic cells within the brain during toxoplasmic encephalitisCD40-CD40 Ligand Interactions Promote Trafficking of CD8+ T Cells into the Brain and Protection against West Nile Virus EncephalitisHow Natalizumab Binds and Antagonizes 4 IntegrinsReview of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosisTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisCheckpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous SystemDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabNo quiet surrender: molecular guardians in multiple sclerosis brainRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisCOX-2 inhibitors vs. NSAIDs in gastrointestinal damage and preventionNatalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisTargeting leukocyte integrins in human diseasesThe blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting
P2860
Q21090888-AF190D22-0C26-44F1-A152-5C51ED54BB46Q21195861-3522E80B-72E5-467E-B273-363C8CCE4A2FQ21245055-0AE8EEB1-BDB2-4989-BA5B-816229FD7EEDQ22242305-4210DB2E-5AA4-4B67-A70C-6A9495EC70B2Q24187126-56FB871C-ED31-4A03-81D2-1B9C705CDA61Q24188270-83440715-70AF-4139-865E-59A838E03248Q24235861-D32578D6-FFB9-4417-BD06-DF6CE1BEF460Q24241982-E4DD7961-F142-4308-A575-A6D45158BD3CQ24309146-63A15439-4499-404C-A7EC-B7E22D4D8B8AQ24563395-AD635DD3-4C9A-44DE-B592-401ACBD2360BQ24621645-FF64C913-4AD2-406D-9CDA-1543DDFA9691Q24629115-BAD162FF-E6D8-496A-8513-57A46C27C258Q24647794-CE06BA75-17E8-4355-A4F6-76001B9DD48BQ24675638-EAF158DC-0065-4A0F-9EA5-A20463F0479FQ26745562-14D8C0AD-9555-4C53-ADB3-264756E104D4Q26750456-A8EB5E09-87DD-4F11-A027-FBC0CF7D85DEQ26770818-B184CFF4-5A74-4CBD-B371-8465053C5098Q26773026-186B2FB4-C354-4CDA-9BE4-6AEC8F8BB1BDQ26776234-B826C48E-4AE5-43F7-8EEA-C41A89CB3F79Q26822611-201C2745-619B-4B2F-B46E-CE4EB8542F73Q26822941-3A0A3773-595D-452A-ADCC-00ADB4D784BDQ26823691-E547D92F-9123-4FD1-9485-02C20638DC4BQ26826930-3392E1B6-0A0A-42D3-912C-A0C82B7A078EQ26861256-7CBB326E-C162-4391-B589-DB7F97E2CAC5Q26999705-09D8ACBE-A91F-4AE0-B355-019DB40E8695Q27009769-95008991-FDF1-4F90-BED3-5FDC61EB72D6Q27021612-DFAE6285-93C5-4F05-91B5-2E5E7938D5FBQ27349006-9BE6C3EA-AEC3-4EEB-BADF-589278FEE3EAQ27481468-79A713A5-11F8-4F49-B367-F9C5F1D5F362Q27679979-6FB9C927-5FCA-4F8A-B848-66747C4C741FQ27693249-ADC4F22E-7F9C-47E5-9434-CE12FBD11027Q28066677-0B502CCD-DFBD-4FEB-BA3B-10DB16B7F6EFQ28066906-4475ABFF-D9D9-46F3-A289-17728275972CQ28083872-1ACDC5E9-6B12-4738-82AC-474CC35AFE71Q28084633-D840F888-1A2F-4F8B-8C06-BE0E48728EC4Q28087414-6C293072-DF6B-4064-830A-A115A6093606Q28182917-BDF99E7C-7882-4A8B-B74C-EDE2AA200E20Q28277470-1740447A-B5AC-4D03-B530-0E48D6B20E65Q28293910-E81F083F-AECE-4AB2-867C-8EDAD8F5C9A7Q28299076-27A4F257-EC49-427D-AB6D-137F595775AC
P2860
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Prevention of experimental aut ...... ainst alpha 4 beta 1 integrin.
@en
Prevention of experimental aut ...... ainst alpha 4 beta 1 integrin.
@nl
type
label
Prevention of experimental aut ...... ainst alpha 4 beta 1 integrin.
@en
Prevention of experimental aut ...... ainst alpha 4 beta 1 integrin.
@nl
prefLabel
Prevention of experimental aut ...... ainst alpha 4 beta 1 integrin.
@en
Prevention of experimental aut ...... ainst alpha 4 beta 1 integrin.
@nl
P2093
P356
P1433
P1476
Prevention of experimental aut ...... ainst alpha 4 beta 1 integrin.
@en
P2093
P2888
P356
10.1038/356063A0
P407
P577
1992-03-01T00:00:00Z
P6179
1001855171